Farallon Capital adds a new position in Covidien
Ireland-based Covidien is a global healthcare leader that offers innovative medical technology solutions and patient care products to providers.
Farallon Capital exits its position in Time Warner Cable
In February, Comcast agreed to buy Time Warner Cable for ~$45.2 billion. This deal will create the largest cable provider in the U.S.
Farallon Capital raises its position in Safeway
On March 6, 2014, grocery store operators Safeway and Albertsons announced a merger agreement valued at approximately $9 billion.
Must-know: Is the Time Warner Cable–Comcast deal a “do?”
Arbs generally avoid utility deals—and for good reason. Typically, the companies have an aggressive expected timeline and these deals don’t close on time.
Farallon Capital establishes a new position in Hillshire Brands
Hillshire reported fiscal 4Q14 net sales of $1.1 billion, up 10.7% in comparison to the corresponding period last year.
Novartis Aims to Turn Around Its Surgical Business in 2017
In 2016, the surgical business of Alcon, Novartis’s (NVS) Consumables segment, witnessed a solid demand trend.
Renaissance Technologies starts new position in Gilead Sciences
In February 2015, Gilead announced its 4Q14 results and reported revenues of $7.3 billion, a significant increase of 137% compared to $3.1 billion for 4Q13.
Chilton Investment Company raises its stake in Covidien plc
Chilton Investment added to its position in Covidien plc (COV) in 4Q14. The position accounts for 3.22% of the fund’s 4Q14 portfolio, up from 0.49% in 3Q14.
Farallon Capital ups stake in Covidien
Farallon Capital Management increased its position in Covidien plc (COV) during the third quarter. The stock accounted for 5.06% of the fund’s total 3Q14 portfolio.
Strategic rationale for the Time Warner Cable–Comcast deal
On February 12, 2014, Time Warner Cable (TWC) and Comcast (CMCSA) agreed to merge. The two companies provide cable TV and broadband access separate geographic areas.
Why consider possible Integrys–Wisconsin Energy merger scenarios?
In the risk arbitrage world, a 2% spread means a deal without much “hair” on it. The market is assigning a high probability of closing.
Should you get involved in the Integrys–Wisconsin Energy deal?
In merger arbitrage, you’ll generally buy the acquired company’s stock and sell short the acquiring company’s stock. So how will this play out when you look at the Integrys-Wisconsin deal?
Spread analysis: Does the Covidien-Medtronic merger make sense?
To perform merger arbitrage, the investor will generally buy the stock of the company being acquired and sell short the stock of the acquiring company.
Key overview: Merger arbitrage and the Covidien-Medtronic deal
The Covidien-Medtronic deal is a scheme of arrangement, which is an English-style merger where a court has to approve the transaction once the votes are in.
Understanding the rationale for the Covidien-Medtronic transaction
On June 15, 2014, Medtronic (MDT) and Covidien (COV) reached an agreement to merge via a scheme of arrangement. The two companies more or less offer complementary goods.
The Covidien-Medtronic merger: Key background on Covidien
Covidien PLC (COV) describes itself as “a global leader in the development, manufacture and sale of healthcare products for use in clinical and home settings.”
A guide to Iridian Asset Management’s investment strategy
As of September 30, 2013, Iridian’s assets under management totaled $10.1 billion in U.S. mid-cap and small-cap equity strategies.
Is renal denervation a new medical device stocks cash cow?
No US companies have approved renal denervation devices in the US market, but they’re in the process of testing and selling these devices.
Are Covidien’s layoffs good for the medical device industry?
Covidien (COV) announced that it will lay off a significant amount of employees as part of global restructuring efforts. The initiative aims to save the company up to $300 million a year by fiscal 2018.
Why Israel is poised to soon lead medical device industry growth
Espicom Business Intelligence forecasts the Israeli market to be valued at $1.096 billion in 2016—a 20% increase over five years. The country looks to the medical device industry for a significant amount of growth.